Literature DB >> 21506072

Minimal invasive biopsy results of "uncertain malignant potential" in digital mammography screening: high prevalence but also high predictive value for malignancy.

S Weigel1, T Decker, E Korsching, C Biesheuvel, A Wöstmann, W Böcker, D Hungermann, K Roterberg, J Tio, W Heindel.   

Abstract

PURPOSE: To evaluate the rate, the histological spectrum and the positive predictive value (PPV) for malignancy of minimally invasive biopsies with "uncertain malignant potential (B3)" in digital mammography screening. METHODS AND MATERIALS: Consecutive data of 37,178 participants of one digital unit of the German screening program were included.
RESULTS: The B 3 rate was 15.1 % (148 / 979). The frequencies of lesion subtypes were as follows: atypical epithelial proliferation of ductal type (AEPDT) 35.1 % (52 / 148), radial scar (RS) 28.4 % (42 / 148), papillary lesions (PAP) 20.3 % (30 / 148), lobular carcinoma in situ 8.8 % (13 / 148), flat epithelial atypia 5.4 % (8 / 148), and mucocele-like lesions 2.0 % (3 / 148). The PPV for malignancy in surgical excisions was overall 0.28 (25 / 91); in detail 0.40 (19 / 47) for AEPDT, 0.20 (5 / 25) for RS, 0.08 (1 / 12) for PAP.
CONCLUSION: Despite a higher B 3 rate of minimally invasive biopsies with "uncertain malignant potential" in digital screening, the benign surgical biopsy rate is not disproportionally increased compared with analog screening programs. Together with defined management protocols, this results in an increased cancer detection rate per screening participant with surgical excision. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2011        PMID: 21506072     DOI: 10.1055/s-0031-1273330

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  7 in total

1.  Malignancy Rate and Malignancy Risk Assessment in Different Lesions of Uncertain Malignant Potential in the Breast (B3 Lesions): An Analysis of 192 Cases from a Single Institution.

Authors:  Svjetlana Mohrmann; Anna Maier-Bode; Frederic Dietzel; Petra Reinecke; Natalia Krawczyk; Thomas Kaleta; Ulrike Kreimer; Gerald Antoch; Tanja N Fehm; Katrin Sabine Roth
Journal:  Breast Care (Basel)       Date:  2021-07-01       Impact factor: 2.268

2.  B3-lesions of the breast and cancer risk - an analysis of mammography screening patients.

Authors:  Oliver Hoffmann; Gesina Athina Stamatis; Ann-Kathrin Bittner; Georg Arnold; Rolf Schnabel; Karlgeorg Krüger; Rainer Kimmig; Martin Heubner
Journal:  Mol Clin Oncol       Date:  2016-02-23

3.  Use of an Additional Diagnostic Work-up Following a Treatment Recommendation from the Preoperative Conference of the Mammography Screening Units.

Authors:  K-J Winzer; S Unger; U Bick; F Dieckmann; E Fallenberg
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-04       Impact factor: 2.915

4.  Lesions of "uncertain malignant potential" in the breast (B3) identified with mammography screening.

Authors:  Christiane Richter-Ehrenstein; Katharina Maak; Sonja Röger; Tilman Ehrenstein
Journal:  BMC Cancer       Date:  2018-08-16       Impact factor: 4.430

5.  A ten-year, single-center experience: Concordance between breast core needle biopsy/vacuum-assisted biopsy and postoperative histopathology in B3 and B5a cases.

Authors:  Mohamed Elsharkawy; Thomas Vestring; Hans-Juergen Raatschen
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

6.  Lesions with unclear malignant potential (B3) after minimally invasive breast biopsy: evaluation of vacuum biopsies performed in Switzerland and recommended further management.

Authors:  Camilla Saladin; Harald Haueisen; Gert Kampmann; Christian Oehlschlegel; B Seifert; Luzi Rageth; Christoph Rageth; S Stadlmann; Rahel A Kubik-Huch
Journal:  Acta Radiol       Date:  2015-11-08       Impact factor: 1.990

7.  Malignancy rates of B3-lesions in breast magnetic resonance imaging - do all lesions have to be excised?

Authors:  H Preibsch; L K Wanner; A Staebler; M Hahn; K C Siegmann-Luz
Journal:  BMC Med Imaging       Date:  2018-09-10       Impact factor: 1.930

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.